Sustained-release of levodopa: single dose study of a new formulation
Identifieur interne : 000279 ( Main/Corpus ); précédent : 000278; suivant : 000280Sustained-release of levodopa: single dose study of a new formulation
Auteurs : M. Gerlach ; W. Kuhn ; Th. Müller ; P. Klotz ; H. PrzuntekSource :
- Journal of Neural Transmission [ 0300-9564 ] ; 1996-06-01.
Abstract
Summary: Motor fluctuations and dyskinesias in Parkinsonian patients may be at least partially due to fluctuations of levodopa plasma concentrations. Sustained-release (SR) formulations of levodopa may present a promising, effective solution of this problem. Therefore we performed a 4-fold, crossover double-blind trial with a new SR preparation, tested in healthy volunteers (Gerlach et al., 1988) before, in 12 Parkinsonian subjects. Two different dosages of the pure new levodopa SR-preparation, a composition of 70% SR and 30% levodopa immediate release (IR) and a conventional IR levodopa preparation were compared by their pharmacokinetic behaviour and their clinical effects. The relative bioavailability of levodopa in plasma was 69% for the combination of SR and IR levodopa release, for the pure SR formulations (100mg levodopa) 54% and (200 mg levodopa) 55%, compared to the 100% of the standard form of IR release of 100 mg levodopa. In contrast to the conventional IR formulation the pharmacokinetic behaviour of the SR preparations showed no initial sharp peak, but more continuous and longer maintaining plasma concentrations of levodopa. Due to the small numbers of cases and the missing homogenity of the selected patients no statistical significant differences between the four preparations regarding the clinical response were observed. But the described pharmacokinetic behaviour gives hope, that these newly developed SR-preparations may lead to progress in the treatment of Parkinson's disease (prolongation of dosage intervals, reduction of motor fluctuations).
Url:
DOI: 10.1007/BF01271231
Links to Exploration step
ISTEX:D8EA2B549FFC2A9C3FB429DACF1357BA7B14887FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sustained-release of levodopa: single dose study of a new formulation</title><author><name sortKey="Gerlach, M" sort="Gerlach, M" uniqKey="Gerlach M" first="M." last="Gerlach">M. Gerlach</name><affiliation><mods:affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, Neurochemistry, University of Würzburg, Würzburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Kuhn, W" sort="Kuhn, W" uniqKey="Kuhn W" first="W." last="Kuhn">W. Kuhn</name><affiliation><mods:affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</mods:affiliation></affiliation></author><author><name sortKey="Muller, Th" sort="Muller, Th" uniqKey="Muller T" first="Th." last="Müller">Th. Müller</name><affiliation><mods:affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</mods:affiliation></affiliation></author><author><name sortKey="Klotz, P" sort="Klotz, P" uniqKey="Klotz P" first="P." last="Klotz">P. Klotz</name><affiliation><mods:affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</mods:affiliation></affiliation></author><author><name sortKey="Przuntek, H" sort="Przuntek, H" uniqKey="Przuntek H" first="H." last="Przuntek">H. Przuntek</name><affiliation><mods:affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D8EA2B549FFC2A9C3FB429DACF1357BA7B14887F</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1007/BF01271231</idno><idno type="url">https://api.istex.fr/document/D8EA2B549FFC2A9C3FB429DACF1357BA7B14887F/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000279</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Sustained-release of levodopa: single dose study of a new formulation</title><author><name sortKey="Gerlach, M" sort="Gerlach, M" uniqKey="Gerlach M" first="M." last="Gerlach">M. Gerlach</name><affiliation><mods:affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, Neurochemistry, University of Würzburg, Würzburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Kuhn, W" sort="Kuhn, W" uniqKey="Kuhn W" first="W." last="Kuhn">W. Kuhn</name><affiliation><mods:affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</mods:affiliation></affiliation></author><author><name sortKey="Muller, Th" sort="Muller, Th" uniqKey="Muller T" first="Th." last="Müller">Th. Müller</name><affiliation><mods:affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</mods:affiliation></affiliation></author><author><name sortKey="Klotz, P" sort="Klotz, P" uniqKey="Klotz P" first="P." last="Klotz">P. Klotz</name><affiliation><mods:affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</mods:affiliation></affiliation></author><author><name sortKey="Przuntek, H" sort="Przuntek, H" uniqKey="Przuntek H" first="H." last="Przuntek">H. Przuntek</name><affiliation><mods:affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neural Transmission</title><title level="j" type="sub">Basic neurosciences and genetics, Parkinson's disease and allied conditions, Alzheimer's disease and related disorders, biological psychiatry</title><title level="j" type="abbrev">J. Neural Transmission</title><idno type="ISSN">0300-9564</idno><idno type="eISSN">1435-1463</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><date type="published" when="1996-06-01">1996-06-01</date><biblScope unit="volume">103</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="717">717</biblScope><biblScope unit="page" to="727">727</biblScope></imprint><idno type="ISSN">0300-9564</idno></series><idno type="istex">D8EA2B549FFC2A9C3FB429DACF1357BA7B14887F</idno><idno type="DOI">10.1007/BF01271231</idno><idno type="ArticleID">Art7</idno><idno type="ArticleID">BF01271231</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0300-9564</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: Motor fluctuations and dyskinesias in Parkinsonian patients may be at least partially due to fluctuations of levodopa plasma concentrations. Sustained-release (SR) formulations of levodopa may present a promising, effective solution of this problem. Therefore we performed a 4-fold, crossover double-blind trial with a new SR preparation, tested in healthy volunteers (Gerlach et al., 1988) before, in 12 Parkinsonian subjects. Two different dosages of the pure new levodopa SR-preparation, a composition of 70% SR and 30% levodopa immediate release (IR) and a conventional IR levodopa preparation were compared by their pharmacokinetic behaviour and their clinical effects. The relative bioavailability of levodopa in plasma was 69% for the combination of SR and IR levodopa release, for the pure SR formulations (100mg levodopa) 54% and (200 mg levodopa) 55%, compared to the 100% of the standard form of IR release of 100 mg levodopa. In contrast to the conventional IR formulation the pharmacokinetic behaviour of the SR preparations showed no initial sharp peak, but more continuous and longer maintaining plasma concentrations of levodopa. Due to the small numbers of cases and the missing homogenity of the selected patients no statistical significant differences between the four preparations regarding the clinical response were observed. But the described pharmacokinetic behaviour gives hope, that these newly developed SR-preparations may lead to progress in the treatment of Parkinson's disease (prolongation of dosage intervals, reduction of motor fluctuations).</div></front></TEI><istex><corpusName>springer</corpusName><author><json:item><name>M. Gerlach</name><affiliations><json:string>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</json:string><json:string>Department of Psychiatry, Neurochemistry, University of Würzburg, Würzburg, Germany</json:string></affiliations></json:item><json:item><name>W. Kuhn</name><affiliations><json:string>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</json:string></affiliations></json:item><json:item><name>Th. Müller</name><affiliations><json:string>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</json:string></affiliations></json:item><json:item><name>P. Klotz</name><affiliations><json:string>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</json:string></affiliations></json:item><json:item><name>H. Przuntek</name><affiliations><json:string>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</json:string></affiliations></json:item></author><articleId><json:string>Art7</json:string><json:string>BF01271231</json:string></articleId><language><json:string>eng</json:string></language><abstract>Summary: Motor fluctuations and dyskinesias in Parkinsonian patients may be at least partially due to fluctuations of levodopa plasma concentrations. Sustained-release (SR) formulations of levodopa may present a promising, effective solution of this problem. Therefore we performed a 4-fold, crossover double-blind trial with a new SR preparation, tested in healthy volunteers (Gerlach et al., 1988) before, in 12 Parkinsonian subjects. Two different dosages of the pure new levodopa SR-preparation, a composition of 70% SR and 30% levodopa immediate release (IR) and a conventional IR levodopa preparation were compared by their pharmacokinetic behaviour and their clinical effects. The relative bioavailability of levodopa in plasma was 69% for the combination of SR and IR levodopa release, for the pure SR formulations (100mg levodopa) 54% and (200 mg levodopa) 55%, compared to the 100% of the standard form of IR release of 100 mg levodopa. In contrast to the conventional IR formulation the pharmacokinetic behaviour of the SR preparations showed no initial sharp peak, but more continuous and longer maintaining plasma concentrations of levodopa. Due to the small numbers of cases and the missing homogenity of the selected patients no statistical significant differences between the four preparations regarding the clinical response were observed. But the described pharmacokinetic behaviour gives hope, that these newly developed SR-preparations may lead to progress in the treatment of Parkinson's disease (prolongation of dosage intervals, reduction of motor fluctuations).</abstract><qualityIndicators><score>7.111</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 774 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1585</abstractCharCount><pdfWordCount>4351</pdfWordCount><pdfCharCount>26986</pdfCharCount><pdfPageCount>11</pdfPageCount><abstractWordCount>230</abstractWordCount></qualityIndicators><title>Sustained-release of levodopa: single dose study of a new formulation</title><genre><json:string>research-article</json:string></genre><host><volume>103</volume><pages><last>727</last><first>717</first></pages><issn><json:string>0300-9564</json:string></issn><issue>6</issue><subject><json:item><value>Pharmacology/Toxicology</value></json:item><json:item><value>Neurology</value></json:item><json:item><value>Psychiatry</value></json:item></subject><journalId><json:string>702</json:string></journalId><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1435-1463</json:string></eissn><title>Journal of Neural Transmission</title><publicationDate>1996</publicationDate><copyrightDate>1996</copyrightDate></host><publicationDate>1996</publicationDate><copyrightDate>1996</copyrightDate><doi><json:string>10.1007/BF01271231</json:string></doi><id>D8EA2B549FFC2A9C3FB429DACF1357BA7B14887F</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/D8EA2B549FFC2A9C3FB429DACF1357BA7B14887F/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/D8EA2B549FFC2A9C3FB429DACF1357BA7B14887F/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/D8EA2B549FFC2A9C3FB429DACF1357BA7B14887F/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Sustained-release of levodopa: single dose study of a new formulation</title><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><availability><p>SPRINGER</p></availability><date>1995-08-28</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Sustained-release of levodopa: single dose study of a new formulation</title><author><persName><forename type="first">M.</forename><surname>Gerlach</surname></persName><affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</affiliation><affiliation>Department of Psychiatry, Neurochemistry, University of Würzburg, Würzburg, Germany</affiliation></author><author><persName><forename type="first">W.</forename><surname>Kuhn</surname></persName><affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</affiliation></author><author><persName><forename type="first">Th.</forename><surname>Müller</surname></persName><affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</affiliation></author><author><persName><forename type="first">P.</forename><surname>Klotz</surname></persName><affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</affiliation></author><author><persName><forename type="first">H.</forename><surname>Przuntek</surname></persName><affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</affiliation></author></analytic><monogr><title level="j">Journal of Neural Transmission</title><title level="j" type="sub">Basic neurosciences and genetics, Parkinson's disease and allied conditions, Alzheimer's disease and related disorders, biological psychiatry</title><title level="j" type="abbrev">J. Neural Transmission</title><idno type="JournalID">702</idno><idno type="pISSN">0300-9564</idno><idno type="eISSN">1435-1463</idno><idno type="IssueArticleCount">12</idno><idno type="VolumeIssueCount">12</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><date type="published" when="1996-06-01"></date><biblScope unit="volume">103</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="717">717</biblScope><biblScope unit="page" to="727">727</biblScope></imprint></monogr><idno type="istex">D8EA2B549FFC2A9C3FB429DACF1357BA7B14887F</idno><idno type="DOI">10.1007/BF01271231</idno><idno type="ArticleID">Art7</idno><idno type="ArticleID">BF01271231</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1995-08-28</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Summary: Motor fluctuations and dyskinesias in Parkinsonian patients may be at least partially due to fluctuations of levodopa plasma concentrations. Sustained-release (SR) formulations of levodopa may present a promising, effective solution of this problem. Therefore we performed a 4-fold, crossover double-blind trial with a new SR preparation, tested in healthy volunteers (Gerlach et al., 1988) before, in 12 Parkinsonian subjects. Two different dosages of the pure new levodopa SR-preparation, a composition of 70% SR and 30% levodopa immediate release (IR) and a conventional IR levodopa preparation were compared by their pharmacokinetic behaviour and their clinical effects. The relative bioavailability of levodopa in plasma was 69% for the combination of SR and IR levodopa release, for the pure SR formulations (100mg levodopa) 54% and (200 mg levodopa) 55%, compared to the 100% of the standard form of IR release of 100 mg levodopa. In contrast to the conventional IR formulation the pharmacokinetic behaviour of the SR preparations showed no initial sharp peak, but more continuous and longer maintaining plasma concentrations of levodopa. Due to the small numbers of cases and the missing homogenity of the selected patients no statistical significant differences between the four preparations regarding the clinical response were observed. But the described pharmacokinetic behaviour gives hope, that these newly developed SR-preparations may lead to progress in the treatment of Parkinson's disease (prolongation of dosage intervals, reduction of motor fluctuations).</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>Medicine & Public Health</head><item><term>Pharmacology/Toxicology</term></item><item><term>Neurology</term></item><item><term>Psychiatry</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1995-08-28">Created</change><change when="1996-06-01">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-2">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/D8EA2B549FFC2A9C3FB429DACF1357BA7B14887F/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Springer, Publisher found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer-Verlag</PublisherName><PublisherLocation>Vienna</PublisherLocation></PublisherInfo><Journal><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>702</JournalID><JournalPrintISSN>0300-9564</JournalPrintISSN><JournalElectronicISSN>1435-1463</JournalElectronicISSN><JournalTitle>Journal of Neural Transmission</JournalTitle><JournalSubTitle>Basic neurosciences and genetics, Parkinson's disease and allied conditions, Alzheimer's disease and related disorders, biological psychiatry</JournalSubTitle><JournalAbbreviatedTitle>J. Neural Transmission</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Medicine & Public Health</JournalSubject><JournalSubject Type="Secondary">Pharmacology/Toxicology</JournalSubject><JournalSubject Type="Secondary">Neurology</JournalSubject><JournalSubject Type="Secondary">Psychiatry</JournalSubject></JournalSubjectGroup></JournalInfo><Volume><VolumeInfo VolumeType="Regular" TocLevels="0"><VolumeIDStart>103</VolumeIDStart><VolumeIDEnd>103</VolumeIDEnd><VolumeIssueCount>12</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular"><IssueInfo TocLevels="0"><IssueIDStart>6</IssueIDStart><IssueIDEnd>6</IssueIDEnd><IssueArticleCount>12</IssueArticleCount><IssueHistory><CoverDate><DateString>1996</DateString><Year>1996</Year><Month>6</Month></CoverDate></IssueHistory><IssueCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>1996</CopyrightYear></IssueCopyright></IssueInfo><Article ID="Art7"><ArticleInfo Language="En" ArticleType="OriginalPaper" NumberingStyle="Unnumbered" TocLevels="0" ContainsESM="No"><ArticleID>BF01271231</ArticleID><ArticleDOI>10.1007/BF01271231</ArticleDOI><ArticleSequenceNumber>7</ArticleSequenceNumber><ArticleTitle Language="En">Sustained-release of levodopa: single dose study of a new formulation</ArticleTitle><ArticleSubCategory>Parkinson's Disease and Allied Conditions</ArticleSubCategory><ArticleFirstPage>717</ArticleFirstPage><ArticleLastPage>727</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2005</Year><Month>2</Month><Day>21</Day></RegistrationDate><Received><Year>1995</Year><Month>8</Month><Day>28</Day></Received><Accepted><Year>1996</Year><Month>2</Month><Day>21</Day></Accepted></ArticleHistory><ArticleCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>1996</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants><ArticleContext><JournalID>702</JournalID><VolumeIDStart>103</VolumeIDStart><VolumeIDEnd>103</VolumeIDEnd><IssueIDStart>6</IssueIDStart><IssueIDEnd>6</IssueIDEnd></ArticleContext></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1 Aff2"><AuthorName DisplayOrder="Western"><GivenName>M.</GivenName><FamilyName>Gerlach</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1" PresentAffiliationID="Aff1"><AuthorName DisplayOrder="Western"><GivenName>W.</GivenName><FamilyName>Kuhn</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Th.</GivenName><FamilyName>Müller</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>P.</GivenName><FamilyName>Klotz</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>H.</GivenName><FamilyName>Przuntek</FamilyName></AuthorName></Author><Affiliation ID="Aff1"><OrgDivision>Department of Neurology, St. Josef Hospital</OrgDivision><OrgName>Ruhr University</OrgName><OrgAddress><City>Bochum</City></OrgAddress></Affiliation><Affiliation ID="Aff2"><OrgDivision>Department of Psychiatry, Neurochemistry</OrgDivision><OrgName>University of Würzburg</OrgName><OrgAddress><City>Würzburg</City><Country>Germany</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En"><Heading>Summary</Heading><Para>Motor fluctuations and dyskinesias in Parkinsonian patients may be at least partially due to fluctuations of levodopa plasma concentrations. Sustained-release (SR) formulations of levodopa may present a promising, effective solution of this problem. Therefore we performed a 4-fold, crossover double-blind trial with a new SR preparation, tested in healthy volunteers (Gerlach et al., 1988) before, in 12 Parkinsonian subjects. Two different dosages of the pure new levodopa SR-preparation, a composition of 70% SR and 30% levodopa immediate release (IR) and a conventional IR levodopa preparation were compared by their pharmacokinetic behaviour and their clinical effects. The relative bioavailability of levodopa in plasma was 69% for the combination of SR and IR levodopa release, for the pure SR formulations (100mg levodopa) 54% and (200 mg levodopa) 55%, compared to the 100% of the standard form of IR release of 100 mg levodopa. In contrast to the conventional IR formulation the pharmacokinetic behaviour of the SR preparations showed no initial sharp peak, but more continuous and longer maintaining plasma concentrations of levodopa. Due to the small numbers of cases and the missing homogenity of the selected patients no statistical significant differences between the four preparations regarding the clinical response were observed. But the described pharmacokinetic behaviour gives hope, that these newly developed SR-preparations may lead to progress in the treatment of Parkinson's disease (prolongation of dosage intervals, reduction of motor fluctuations).</Para></Abstract><KeywordGroup Language="En"><Heading>Keywords</Heading><Keyword>Levodopa</Keyword><Keyword>parkinsonian therapy</Keyword><Keyword>pharmacokinetics of levodopa</Keyword><Keyword>sustained-release levodopa</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Sustained-release of levodopa: single dose study of a new formulation</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Sustained-release of levodopa: single dose study of a new formulation</title></titleInfo><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Gerlach</namePart><affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</affiliation><affiliation>Department of Psychiatry, Neurochemistry, University of Würzburg, Würzburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W.</namePart><namePart type="family">Kuhn</namePart><affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Th.</namePart><namePart type="family">Müller</namePart><affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Klotz</namePart><affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Przuntek</namePart><affiliation>Department of Neurology, St. Josef Hospital, Ruhr University, Bochum</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper"></genre><originInfo><publisher>Springer-Verlag</publisher><place><placeTerm type="text">Vienna</placeTerm></place><dateCreated encoding="w3cdtf">1995-08-28</dateCreated><dateIssued encoding="w3cdtf">1996-06-01</dateIssued><copyrightDate encoding="w3cdtf">1996</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Summary: Motor fluctuations and dyskinesias in Parkinsonian patients may be at least partially due to fluctuations of levodopa plasma concentrations. Sustained-release (SR) formulations of levodopa may present a promising, effective solution of this problem. Therefore we performed a 4-fold, crossover double-blind trial with a new SR preparation, tested in healthy volunteers (Gerlach et al., 1988) before, in 12 Parkinsonian subjects. Two different dosages of the pure new levodopa SR-preparation, a composition of 70% SR and 30% levodopa immediate release (IR) and a conventional IR levodopa preparation were compared by their pharmacokinetic behaviour and their clinical effects. The relative bioavailability of levodopa in plasma was 69% for the combination of SR and IR levodopa release, for the pure SR formulations (100mg levodopa) 54% and (200 mg levodopa) 55%, compared to the 100% of the standard form of IR release of 100 mg levodopa. In contrast to the conventional IR formulation the pharmacokinetic behaviour of the SR preparations showed no initial sharp peak, but more continuous and longer maintaining plasma concentrations of levodopa. Due to the small numbers of cases and the missing homogenity of the selected patients no statistical significant differences between the four preparations regarding the clinical response were observed. But the described pharmacokinetic behaviour gives hope, that these newly developed SR-preparations may lead to progress in the treatment of Parkinson's disease (prolongation of dosage intervals, reduction of motor fluctuations).</abstract><relatedItem type="host"><titleInfo><title>Journal of Neural Transmission</title><subTitle>Basic neurosciences and genetics, Parkinson's disease and allied conditions, Alzheimer's disease and related disorders, biological psychiatry</subTitle></titleInfo><titleInfo type="abbreviated"><title>J. Neural Transmission</title></titleInfo><genre type="Journal" displayLabel="Archive Journal"></genre><originInfo><dateIssued encoding="w3cdtf">1996-06-01</dateIssued><copyrightDate encoding="w3cdtf">1996</copyrightDate></originInfo><subject><genre>Medicine & Public Health</genre><topic>Pharmacology/Toxicology</topic><topic>Neurology</topic><topic>Psychiatry</topic></subject><identifier type="ISSN">0300-9564</identifier><identifier type="eISSN">1435-1463</identifier><identifier type="JournalID">702</identifier><identifier type="IssueArticleCount">12</identifier><identifier type="VolumeIssueCount">12</identifier><part><date>1996</date><detail type="volume"><number>103</number><caption>vol.</caption></detail><detail type="issue"><number>6</number><caption>no.</caption></detail><extent unit="pages"><start>717</start><end>727</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1996</recordOrigin></recordInfo></relatedItem><identifier type="istex">D8EA2B549FFC2A9C3FB429DACF1357BA7B14887F</identifier><identifier type="DOI">10.1007/BF01271231</identifier><identifier type="ArticleID">Art7</identifier><identifier type="ArticleID">BF01271231</identifier><accessCondition type="use and reproduction" contentType="copyright">Springer-Verlag</accessCondition><recordInfo><recordContentSource>SPRINGER</recordContentSource><recordOrigin>Springer-Verlag, 1996</recordOrigin></recordInfo></mods></metadata><enrichments><istex:refBibTEI uri="https://api.istex.fr/document/D8EA2B549FFC2A9C3FB429DACF1357BA7B14887F/enrichments/refBib"><teiHeader></teiHeader><text><front></front><body></body><back><listBibl><biblStruct xml:id="b0"><analytic><title level="a" type="main">Pathophysiology of L-Dopainduced abnormal involuntary movements</title><author><persName><forename type="first">Y</forename><surname>Agid</surname></persName></author><author><persName><forename type="first">Am</forename><surname>Bonnet</surname></persName></author><author><persName><forename type="first">M</forename><surname>Ruberg</surname></persName></author><author><persName><forename type="first">F</forename><surname>Javoy-Agid</surname></persName></author></analytic><monogr><title level="m">Dyskinesia -research and treatment</title><editor>Chase C, Gerlach C</editor><meeting><address><addrLine>Berlin Heidelberg New York Tokyo</addrLine></address></meeting><imprint><publisher>Springer</publisher><date type="published" when="1985"></date><biblScope unit="page" from="145" to="159"></biblScope></imprint></monogr><note>Suppl. ] 2</note></biblStruct><biblStruct xml:id="b1"><analytic><title level="a" type="main">Plasma levels of levodopa and its main metabolites in Parkinsonian patients after conventional and controlledrelease levodopa-carbidopa associations</title><author><persName><forename type="first">P</forename><surname>Benetello</surname></persName></author><author><persName><forename type="first">M</forename><surname>Furlanut</surname></persName></author><author><persName><forename type="first">G</forename><surname>Zara</surname></persName></author><author><persName><forename type="first">M</forename><surname>Baraldo</surname></persName></author><author><persName><forename type="first">E</forename><surname>Hassan</surname></persName></author></analytic><monogr><title level="j">Eur Neurol</title><imprint><biblScope unit="volume">33</biblScope><biblScope unit="page" from="69" to="73"></biblScope><date type="published" when="1993"></date></imprint></monogr></biblStruct><biblStruct xml:id="b2"><analytic><title level="a" type="main">Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness</title><author><persName><forename type="first">N</forename><surname>Bergemann</surname></persName></author><author><persName><forename type="first">H</forename><surname>Baas</surname></persName></author><author><persName><forename type="first">Pa</forename><surname>Fischer</surname></persName></author></analytic><monogr><title level="j">Nervenarzt</title><imprint><biblScope unit="volume">65</biblScope><biblScope unit="page" from="250" to="257"></biblScope><date type="published" when="1994"></date></imprint></monogr></biblStruct><biblStruct xml:id="b3"><monogr><title level="m" type="main">Controlled-release levodopa</title><author><persName><forename type="first">Jm</forename><surname>Cedarbaum</surname></persName></author><author><persName><forename type="first">L</forename><surname>Breck</surname></persName></author><author><persName><forename type="first">H</forename><surname>Kutt</surname></persName></author><imprint><date type="published" when="1987"></date><publisher>Mc Dowell FH</publisher></imprint></monogr></biblStruct><biblStruct xml:id="b4"><analytic><title level="a" type="main">Sinemet CR 4 treatment of response fluctuations in Parkinson's disease</title><author><persName><forename type="first">Ii</forename></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">37</biblScope><biblScope unit="page" from="1607" to="1612"></biblScope></imprint></monogr></biblStruct><biblStruct xml:id="b5"><analytic><title level="a" type="main">Bioavailability of L-Dopa after Madopar HBS administration in healthy volunteers</title><author><persName><forename type="first">Ch</forename><surname>Chrevoisier</surname></persName></author><author><persName><forename type="first">B</forename><surname>Hoevels</surname></persName></author><author><persName><forename type="first">G</forename><surname>Zurcher</surname></persName></author><author><persName><forename type="first">Da</forename><surname>Prada</surname></persName></author><author><persName><forename type="first">M</forename></persName></author></analytic><monogr><title level="j">Eur Neurol</title><editor>Marsden CD, Rinne UK, Koella WP, Dubius R (eds) (Madopar) HBS. Karger</editor><imprint><biblScope unit="volume">27</biblScope><biblScope unit="page" from="36" to="46"></biblScope><date type="published" when="1987"></date></imprint></monogr><note>Suppl. ] 1</note></biblStruct><biblStruct xml:id="b6"><analytic><title level="a" type="main">Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease</title><author><persName><forename type="first">M</forename><surname>Contin</surname></persName></author><author><persName><forename type="first">R</forename><surname>Riva</surname></persName></author><author><persName><forename type="first">P</forename><surname>Martinelli</surname></persName></author><author><persName><forename type="first">P</forename><surname>Cortelli</surname></persName></author><author><persName><forename type="first">F</forename><surname>Albani</surname></persName></author><author><persName><forename type="first">A</forename><surname>Baruzzi</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">43</biblScope><biblScope unit="page" from="367" to="371"></biblScope><date type="published" when="1993"></date></imprint></monogr></biblStruct><biblStruct xml:id="b7"><analytic><title level="a" type="main">Postoperative evaluation of 26 selected patients with Parkinson's disease</title><author><persName><forename type="first">Ac</forename><surname>England</surname></persName></author><author><persName><forename type="first">Rs</forename><surname>Schwab</surname></persName></author></analytic><monogr><title level="j">J Am Geriatr Soc</title><imprint><biblScope unit="volume">4</biblScope><biblScope unit="page" from="1219" to="1232"></biblScope><date type="published" when="1956"></date></imprint></monogr></biblStruct><biblStruct xml:id="b8"><analytic><title level="a" type="main">On-off" phenomenon in Parkinson's disease: correlation to concentration of dopa in plasma</title><author><persName><forename type="first">T</forename><surname>Eriksson</surname></persName></author><author><persName><forename type="first">T</forename><surname>Magnusson</surname></persName></author><author><persName><forename type="first">A</forename><surname>Carlsson</surname></persName></author><author><persName><forename type="first">Ak</forename><surname>Granerus</surname></persName></author></analytic><monogr><title level="j">J Neural Transm</title><imprint><biblScope unit="volume">59</biblScope><biblScope unit="page" from="229" to="240"></biblScope><date type="published" when="1984"></date></imprint></monogr></biblStruct><biblStruct xml:id="b9"><analytic><title level="a" type="main">Systemic availability of orally administered L-Dopa in the elderly Parkinsonian patient</title><author><persName><forename type="first">Ma</forename><surname>Evans</surname></persName></author><author><persName><forename type="first">Ej</forename><surname>Triggs</surname></persName></author><author><persName><forename type="first">Ga</forename><surname>Broe</surname></persName></author><author><persName><forename type="first">N</forename><surname>Saines</surname></persName></author></analytic><monogr><title level="j">Eur J Clin Pharmacol</title><imprint><biblScope unit="volume">17</biblScope><biblScope unit="page" from="215" to="221"></biblScope><date type="published" when="1980"></date></imprint></monogr></biblStruct><biblStruct xml:id="b10"><analytic><title level="a" type="main">Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I</title><author><persName><forename type="first">G</forename><surname>Fabbrini</surname></persName></author><author><persName><forename type="first">Mm</forename><surname>Mouradian</surname></persName></author><author><persName><forename type="first">Jl</forename><surname>Juncos</surname></persName></author><author><persName><forename type="first">J</forename><surname>Schlegel</surname></persName></author><author><persName><forename type="first">E</forename><surname>Mohr</surname></persName></author><author><persName><forename type="first">Tn</forename><surname>Chase</surname></persName></author></analytic><monogr><title level="j">Ann Neurol</title><imprint><biblScope unit="volume">24</biblScope><biblScope unit="page" from="366" to="371"></biblScope><date type="published" when="1988"></date></imprint></monogr></biblStruct><biblStruct xml:id="b11"><analytic><title level="a" type="main">On-off" phenomenon with levodopa therapy in parkinsonism</title><author><persName><forename type="first">S</forename><surname>Fahn</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">24</biblScope><biblScope unit="page" from="431" to="441"></biblScope><date type="published" when="1974"></date></imprint></monogr></biblStruct><biblStruct xml:id="b12"><analytic><title level="a" type="main">Determination of L-Dopa and 3-O-methyl- dopa in human plasma by extraction using C18-cartridges followed by highperformance liquid chromatographic analysis with electrochemical detection</title><author><persName><forename type="first">M</forename><surname>Gerlach</surname></persName></author><author><persName><forename type="first">N</forename><surname>Klaunzer</surname></persName></author><author><persName><forename type="first">H</forename><surname>Przuntek</surname></persName></author></analytic><monogr><title level="j">J Chromatogr</title><imprint><biblScope unit="volume">380</biblScope><biblScope unit="page" from="379" to="385"></biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct xml:id="b13"><monogr><title level="m" type="main">Pharmacokinetic studies with sustained-release formulations of levodopa in healthy volunteers Continuous dopaminergic stimulation in Parkinson's disease Pharmacokinetic investigations of various levodopa formulations</title><author><persName><forename type="first">M</forename><surname>Gerlach</surname></persName></author><author><persName><forename type="first">B</forename><surname>Gebhardt</surname></persName></author><author><persName><forename type="first">W</forename><surname>Kuhn</surname></persName></author><author><persName><forename type="first">H</forename><surname>Przuntek</surname></persName></author><editor>Obeso JA, Horowski R, Marsden CD Przuntek H, Riederer P</editor><imprint><date type="published" when="1988"></date><publisher>Springer Springer</publisher><biblScope unit="page" from="211" to="218"></biblScope><pubPlace>Wien New York ; Wien New York</pubPlace></imprint></monogr><note>Key. Topics in Brain Research</note></biblStruct><biblStruct xml:id="b14"><analytic><title level="a" type="main">Dopamine receptor changes in response to prolonged treatment with L-Dopa</title><author><persName><forename type="first">A</forename><surname>Groppetti</surname></persName></author><author><persName><forename type="first">C</forename><surname>Flanto</surname></persName></author><author><persName><forename type="first">E</forename><surname>Parati</surname></persName></author><author><persName><forename type="first">A</forename><surname>Vescovi</surname></persName></author><author><persName><forename type="first">L</forename><surname>Ruscioni</surname></persName></author><author><persName><forename type="first">M</forename><surname>Parenti</surname></persName></author></analytic><monogr><title level="j">J Neural Transm</title><imprint><biblScope unit="volume">22</biblScope><biblScope unit="page" from="33" to="45"></biblScope><date type="published" when="1986"></date></imprint></monogr><note>Suppl. ]</note></biblStruct><biblStruct xml:id="b15"><analytic><title level="a" type="main">Parkinson's disease and motor flutuations: long-acting carbidopa/levodopa (CR-4-Sinemet)</title><author><persName><forename type="first">Cg</forename><surname>Goetz</surname></persName></author><author><persName><forename type="first">Cm</forename><surname>Tanner</surname></persName></author><author><persName><forename type="first">Hl</forename><surname>Klawans</surname></persName></author><author><persName><forename type="first">Km</forename><surname>Shannon</surname></persName></author><author><persName><forename type="first">Vs</forename><surname>Caroll</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">37</biblScope><biblScope unit="page" from="875" to="878"></biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct xml:id="b16"><analytic><title level="a" type="main">Intestinal absorption of levodopa in man</title><author><persName><forename type="first">Ur</forename><surname>Gundert-Remv</surname></persName></author><author><persName><forename type="first">R</forename><surname>Hildebrandt</surname></persName></author><author><persName><forename type="first">A</forename><surname>Stiehl</surname></persName></author><author><persName><forename type="first">E</forename><surname>Weber</surname></persName></author><author><persName><forename type="first">G</forename><surname>Zurcher</surname></persName></author><author><persName><forename type="first">Da</forename><surname>Prada</surname></persName></author><author><persName><forename type="first">M</forename></persName></author></analytic><monogr><title level="j">Eur J Clin Pharmacol</title><imprint><biblScope unit="volume">25</biblScope><date type="published" when="1983"></date></imprint></monogr></biblStruct><biblStruct xml:id="b17"><monogr><title></title><author><persName><forename type="first">S</forename><surname>Harder</surname></persName></author><author><persName><forename type="first">H</forename><surname>Baas</surname></persName></author><author><persName><forename type="first">N</forename><surname>Bergemann</surname></persName></author><author><persName><forename type="first">L</forename><surname>Demisch</surname></persName></author><author><persName><forename type="first">S</forename><surname>Rietbrock</surname></persName></author><imprint><date type="published" when="1995"></date><biblScope unit="page" from="Concentration" to="effect"></biblScope></imprint></monogr></biblStruct><biblStruct xml:id="b18"><analytic><title level="a" type="main">Pharmacokinetics of levodopa and motor fluctuations</title><author><persName><forename type="first">Rj</forename><surname>Hardie</surname></persName></author><author><persName><forename type="first">Aj</forename><surname>Lees</surname></persName></author><author><persName><forename type="first">Gm</forename><surname>Stern</surname></persName></author></analytic><monogr><title level="j">Adv Neurol</title><editor>Yahr MD, Bergmann KJ</editor><imprint><publisher>Parkinson's disease. Raven Press</publisher><publisher>Parkinson's disease. Raven Press</publisher><biblScope unit="volume">45</biblScope><biblScope unit="page" from="487" to="492"></biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct xml:id="b19"><analytic><title level="a" type="main">The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations</title><author><persName><forename type="first">Rj</forename><surname>Hardie</surname></persName></author><author><persName><forename type="first">Sl</forename><surname>Malcolm</surname></persName></author><author><persName><forename type="first">Aj</forename><surname>Lees</surname></persName></author><author><persName><forename type="first">Gm</forename><surname>Stern</surname></persName></author><author><persName><forename type="first">Jg</forename><surname>Allen</surname></persName></author></analytic><monogr><title level="j">Br J Clin Pharmacol</title><imprint><biblScope unit="volume">22</biblScope><biblScope unit="page" from="429" to="436"></biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct xml:id="b20"><analytic><title level="a" type="main">Parkinsonism: onset, progression and mortality</title><author><persName><forename type="first">Mm</forename><surname>Hoehn</surname></persName></author><author><persName><forename type="first">Md</forename><surname>Yahr</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">17</biblScope><biblScope unit="page" from="427" to="442"></biblScope><date type="published" when="1967"></date></imprint></monogr></biblStruct><biblStruct xml:id="b21"><analytic><title level="a" type="main">Long acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease</title><author><persName><forename type="first">Jt</forename><surname>Hutton</surname></persName></author><author><persName><forename type="first">Jl</forename><surname>Morris</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">42</biblScope><biblScope unit="page" from="51" to="56"></biblScope><date type="published" when="1992"></date></imprint></monogr><note>Suppl. 1</note></biblStruct><biblStruct xml:id="b22"><monogr><title level="m" type="main">Effect of repeated L-Dopa administration on striatal dopamine receptor function in the rateds) Recent developments in Parkinson's disease</title><author><persName><forename type="first">P</forename><surname>Jenner</surname></persName></author><author><persName><forename type="first">S</forename><surname>Boyse</surname></persName></author><author><persName><forename type="first">Cd</forename><surname>Marsden</surname></persName></author><editor>Fahn S, Marsden CD, Jenner P, Teychenne P (</editor><imprint><date type="published" when="1986"></date><publisher>Raven Press</publisher><biblScope unit="page" from="189" to="203"></biblScope><pubPlace>New York</pubPlace></imprint></monogr></biblStruct><biblStruct xml:id="b23"><analytic><title level="a" type="main">Controlled-release levodopacarbidopa (CR-5) in the management of Parkinsonian motor fluctuations</title><author><persName><forename type="first">Jl</forename><surname>Juncos</surname></persName></author><author><persName><forename type="first">G</forename><surname>Fabbrini</surname></persName></author><author><persName><forename type="first">Mm</forename><surname>Mouradian</surname></persName></author><author><persName><forename type="first">Tn</forename><surname>Chase</surname></persName></author></analytic><monogr><title level="j">Arch Neurol</title><imprint><biblScope unit="volume">44</biblScope><biblScope unit="page" from="1010" to="1012"></biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct xml:id="b24"><analytic><title level="a" type="main">Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients</title><author><persName><forename type="first">B</forename><surname>Kleedorfer</surname></persName></author><author><persName><forename type="first">W</forename><surname>Poewe</surname></persName></author></analytic><monogr><title level="j">J Neural Transm [P~D Sect]</title><imprint><biblScope unit="volume">4</biblScope><biblScope unit="page" from="173" to="178"></biblScope><date type="published" when="1992"></date></imprint></monogr></biblStruct><biblStruct xml:id="b25"><monogr><title level="m" type="main">Motor performance test (eds) Early diagnosis and preventive therapy in Parkinson's disease</title><author><persName><forename type="first">Ph</forename><surname>Kraus</surname></persName></author><author><persName><forename type="first">H</forename><surname>Przuntek</surname></persName></author><editor>Przuntek H, Riederer P</editor><imprint><date type="published" when="1989"></date><publisher>Springer</publisher><biblScope unit="page" from="75" to="83"></biblScope><pubPlace>Wien New York</pubPlace></imprint></monogr></biblStruct><biblStruct xml:id="b26"><analytic><title level="a" type="main">Oral Levodopa/ carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study</title><author><persName><forename type="first">Mc</forename><surname>Kurth</surname></persName></author><author><persName><forename type="first">Jw</forename><surname>Tetrud</surname></persName></author><author><persName><forename type="first">I</forename><surname>Irwin</surname></persName></author><author><persName><forename type="first">Wh</forename><surname>Lyness</surname></persName></author><author><persName><forename type="first">Jw</forename><surname>Langston</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">43</biblScope><biblScope unit="page" from="1036" to="1039"></biblScope><date type="published" when="1993"></date></imprint></monogr></biblStruct><biblStruct xml:id="b27"><monogr><title level="m" type="main">Dopa uptake and dopamine receptor-binding visualized in the human brain in vivoeds) Recent developments in Parkinson's disease</title><author><persName><forename type="first">K</forename><surname>Leenders</surname></persName></author><author><persName><forename type="first">A</forename><surname>Palmer</surname></persName></author><author><persName><forename type="first">D</forename><surname>Turton</surname></persName></author><editor>Fahn S, Marsden CD, Jenner P, Teychenne P (</editor><imprint><date type="published" when="1986"></date><publisher>Raven Press</publisher><biblScope unit="page" from="103" to="113"></biblScope><pubPlace>New York</pubPlace></imprint></monogr></biblStruct><biblStruct xml:id="b28"><analytic><title level="a" type="main">Levodopa therapeutics: new treatment strategies</title><author><persName><forename type="first">Pa</forename><surname>Lewitt</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">43</biblScope><biblScope unit="page" from="31" to="37"></biblScope><date type="published" when="1993"></date></imprint></monogr><note>Suppl. 6</note></biblStruct><biblStruct xml:id="b29"><monogr><title level="m" type="main">Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease</title><author><persName><forename type="first">Mh</forename><surname>Marion</surname></persName></author><author><persName><forename type="first">F</forename><surname>Stocchi</surname></persName></author><author><persName><forename type="first">P</forename><surname>Quinn</surname></persName></author><author><persName><forename type="first">P</forename><surname>Jenner</surname></persName></author><author><persName><forename type="first">Cd</forename><surname>Marsden</surname></persName></author><editor>Yahr MD, Bergmann KJ</editor><imprint><date type="published" when="1987"></date><publisher>Raven Press</publisher><biblScope unit="page" from="493" to="496"></biblScope><pubPlace>New York</pubPlace></imprint></monogr><note>Adv. Neurol 45</note></biblStruct><biblStruct xml:id="b30"><analytic><title level="a" type="main">Fluctuation of disability in Parkinson's disease -clinical aspects</title><author><persName><forename type="first">Cd</forename><surname>Marsden</surname></persName></author><author><persName><forename type="first">Jd</forename><surname>Parkes</surname></persName></author><author><persName><forename type="first">N</forename><surname>Quinn</surname></persName></author></analytic><monogr><title level="m">Movement disorders</title><editor>Marsden CD, Fahn S</editor><meeting><address><addrLine>London</addrLine></address></meeting><imprint><publisher>Butterworth</publisher><date type="published" when="1982"></date><biblScope unit="page" from="96" to="122"></biblScope></imprint></monogr></biblStruct><biblStruct xml:id="b31"><analytic><title level="a" type="main">Objective measurement of human motor activity</title><author><persName><forename type="first">Rj</forename><surname>Mcpartland</surname></persName></author><author><persName><forename type="first">Dj</forename><surname>Kupfer</surname></persName></author><author><persName><forename type="first">Fg</forename><surname>Foster</surname></persName></author><author><persName><forename type="first">Rg</forename><surname>Reisler</surname></persName></author><author><persName><forename type="first">G</forename><surname>Mathews</surname></persName></author></analytic><monogr><title level="j">Biotelemetry</title><imprint><biblScope unit="volume">2</biblScope><biblScope unit="page" from="317" to="323"></biblScope><date type="published" when="1975"></date></imprint></monogr></biblStruct><biblStruct xml:id="b32"><analytic><title level="a" type="main">Biopharmazie -Theorie und Praxis der Pharmakokinetik. G Thieme Central mechanisms and levodopa response fluctuations in Parkinson's disease</title><author><persName><forename type="first">J</forename><surname>Meier</surname></persName></author><author><persName><forename type="first">H</forename><surname>Rettig</surname></persName></author><author><persName><forename type="first">H</forename><surname>Hess</surname></persName></author></analytic><monogr><title level="j">Clin Neuropharmacol</title><imprint><biblScope unit="volume">11</biblScope><biblScope unit="page" from="378" to="385"></biblScope><date type="published" when="1981"></date></imprint></monogr></biblStruct><biblStruct xml:id="b33"><analytic><title level="a" type="main">Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II</title><author><persName><forename type="first">Mm</forename><surname>Mouradian</surname></persName></author><author><persName><forename type="first">Jl</forename><surname>Juncos</surname></persName></author><author><persName><forename type="first">G</forename><surname>Fabbrini</surname></persName></author><author><persName><forename type="first">J</forename><surname>Schlegel</surname></persName></author><author><persName><forename type="first">Jj</forename><surname>Bartko</surname></persName></author><author><persName><forename type="first">Tn</forename><surname>Chase</surname></persName></author></analytic><monogr><title level="j">Ann Neurol</title><imprint><biblScope unit="volume">24</biblScope><biblScope unit="page" from="372" to="378"></biblScope><date type="published" when="1988"></date></imprint></monogr></biblStruct><biblStruct xml:id="b34"><analytic><title level="a" type="main">On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics</title><author><persName><forename type="first">Jg</forename><surname>Nutt</surname></persName></author></analytic><monogr><title level="j">Ann Neurol</title><imprint><biblScope unit="volume">22</biblScope><biblScope unit="page" from="535" to="540"></biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct xml:id="b35"><analytic><title level="a" type="main">Levodopa pharmacokinetics and pharmacodynamics in fluctuating Parkinsonian patients</title><author><persName><forename type="first">Jg</forename><surname>Nutt</surname></persName></author><author><persName><forename type="first">Wr</forename><surname>Woodward</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">36</biblScope><biblScope unit="page" from="739" to="744"></biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct xml:id="b36"><analytic><title level="a" type="main">The "On-off" phenomenon in Parkinson' s disease: correlation to levodopa absorption and transport</title><author><persName><forename type="first">Jg</forename><surname>Nutt</surname></persName></author><author><persName><forename type="first">Wr</forename><surname>Woodward</surname></persName></author><author><persName><forename type="first">Jp</forename><surname>Hammerstad</surname></persName></author><author><persName><forename type="first">Jh</forename><surname>Carter</surname></persName></author><author><persName><forename type="first">Jl</forename><surname>Anderson</surname></persName></author></analytic><monogr><title level="j">N Engl J Med</title><imprint><biblScope unit="volume">310</biblScope><biblScope unit="page" from="483" to="488"></biblScope><date type="published" when="1984"></date></imprint></monogr></biblStruct><biblStruct xml:id="b37"><analytic><title level="a" type="main">Clinical and biochemical studies with controlled-release levodopa/carbidopa</title><author><persName><forename type="first">Jg</forename><surname>Nutt</surname></persName></author><author><persName><forename type="first">Wr</forename><surname>Woodward</surname></persName></author><author><persName><forename type="first">Jh</forename><surname>Carter</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">36</biblScope><biblScope unit="page" from="1206" to="1211"></biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct xml:id="b38"><analytic><title level="a" type="main">Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease</title><author><persName><forename type="first">R</forename><surname>Pahwa</surname></persName></author><author><persName><forename type="first">Rn</forename><surname>Busenbark</surname></persName></author><author><persName><forename type="first">D</forename><surname>Michalek</surname></persName></author><author><persName><forename type="first">Jp</forename><surname>Hubble</surname></persName></author><author><persName><forename type="first">Wc</forename><surname>Koller</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">43</biblScope><biblScope unit="page" from="677" to="681"></biblScope><date type="published" when="1993"></date></imprint></monogr></biblStruct><biblStruct xml:id="b39"><analytic><title level="a" type="main">Madopar HBS in fluctuating Parkinsonian patients: two-year treatment</title><author><persName><forename type="first">G</forename><surname>Pezzoli</surname></persName></author><author><persName><forename type="first">S</forename><surname>Tesei</surname></persName></author><author><persName><forename type="first">C</forename><surname>Ferrante</surname></persName></author><author><persName><forename type="first">E</forename><surname>Cossutta</surname></persName></author><author><persName><forename type="first">A</forename><surname>Zecchinelli</surname></persName></author><author><persName><forename type="first">G</forename><surname>Scarlata</surname></persName></author></analytic><monogr><title level="j">Mov Disord</title><imprint><biblScope unit="volume">3</biblScope><biblScope unit="page" from="37" to="45"></biblScope><date type="published" when="1988"></date></imprint></monogr></biblStruct><biblStruct xml:id="b40"><analytic><title level="a" type="main">Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations</title><author><persName><forename type="first">Wh</forename><surname>Poewe</surname></persName></author><author><persName><forename type="first">Aj</forename><surname>Lees</surname></persName></author><author><persName><forename type="first">Gm</forename><surname>Stern</surname></persName></author></analytic><monogr><title level="j">Clin Neuropharmacol</title><imprint><biblScope unit="volume">9</biblScope><biblScope unit="page" from="430" to="439"></biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct xml:id="b41"><analytic><title level="a" type="main">Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and "On-Off" fluctuations</title><author><persName><forename type="first">Np</forename><surname>Quinn</surname></persName></author><author><persName><forename type="first">Mh</forename><surname>Marion</surname></persName></author><author><persName><forename type="first">Cd</forename><surname>Marsden</surname></persName></author></analytic><monogr><title level="j">Eur Neurol</title><editor>Marsden CD, Rinne UK, Koella WP, Dubius R</editor><imprint><publisher>Madopar) HBS. Karger</publisher><publisher>Madopar) HBS. Karger</publisher><biblScope unit="volume">27</biblScope><biblScope unit="page" from="105" to="113"></biblScope><date type="published" when="1987"></date></imprint></monogr><note>Suppl. 1]</note></biblStruct><biblStruct xml:id="b42"><analytic><title level="a" type="main">Pathobiochemistry of the extrapyramidal system: a "short note" review</title><author><persName><forename type="first">P</forename><surname>Riederer</surname></persName></author><author><persName><forename type="first">E</forename><surname>Sofic</surname></persName></author><author><persName><forename type="first">Wd</forename><surname>Rausch</surname></persName></author><author><persName><forename type="first">G</forename><surname>Hebenstreit</surname></persName></author><author><persName><forename type="first">J</forename><surname>Bruinvels</surname></persName></author></analytic><monogr><title level="m">Early diagnosis and preventive therapy in Parkinson' disease</title><editor>Przuntek H, Riederer P</editor><meeting><address><addrLine>Wien New York</addrLine></address></meeting><imprint><publisher>Springer</publisher><date type="published" when="1989"></date><biblScope unit="page" from="139" to="151"></biblScope></imprint></monogr></biblStruct><biblStruct xml:id="b43"><analytic><title level="a" type="main">Motor response to apomorphine and levodopa in asymmetric Parkinson's disease</title><author><persName><forename type="first">M</forename><surname>Rodriguez</surname></persName></author><author><persName><forename type="first">G</forename><surname>Lera</surname></persName></author><author><persName><forename type="first">J</forename><surname>Vaamonde</surname></persName></author><author><persName><forename type="first">Mr</forename><surname>Luquin</surname></persName></author><author><persName><forename type="first">Ja</forename><surname>Obeso</surname></persName></author></analytic><monogr><title level="j">J Neurol Neurosurg Psychiatry</title><imprint><biblScope unit="volume">57</biblScope><biblScope unit="page" from="562" to="566"></biblScope><date type="published" when="1994"></date></imprint></monogr></biblStruct><biblStruct xml:id="b44"><analytic><title level="a" type="main">Clinical trial of Madopar HBS in Parkinsonian patients with fluctuating drug response after long-term levodopa therapy</title><author><persName><forename type="first">P</forename><surname>Rondot</surname></persName></author><author><persName><forename type="first">M</forename><surname>Ziegler</surname></persName></author><author><persName><forename type="first">N</forename><surname>Aymard</surname></persName></author><author><persName><forename type="first">J</forename><surname>Holzer</surname></persName></author></analytic><monogr><title level="j">Eur Neurol</title><editor>Marsden CD, Rinne UK, Koella WP, Dubius R</editor><imprint><publisher>Madopar) HBS. Karger</publisher><publisher>Madopar) HBS. Karger</publisher><biblScope unit="volume">27</biblScope><biblScope unit="page" from="114" to="119"></biblScope><date type="published" when="1987"></date></imprint></monogr><note>Suppl. 1]</note></biblStruct><biblStruct xml:id="b45"><monogr><title level="m" type="main">Die Wertigkeit von L-Dopa-"slow release"-Pr~iparaten in der Behandlung der Parkinson-Krankheit</title><author><persName><forename type="first">L</forename><surname>Schelowsky</surname></persName></author><author><persName><forename type="first">W</forename><surname>Poewe</surname></persName></author><editor>Schimrigk K, Haal3 A, Haman G</editor><imprint><date type="published" when="1992"></date><publisher>Springer</publisher><biblScope unit="page" from="185" to="193"></biblScope><pubPlace>Berlin Heidelberg New York Tokyo</pubPlace></imprint></monogr><note>Hrsg. ) Verhandlungen der deutschen Gesellschaft ffir Neurologie</note></biblStruct><biblStruct xml:id="b46"><analytic><title level="a" type="main">Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study</title><author><persName><forename type="first">F</forename><surname>Stocchi</surname></persName></author><author><persName><forename type="first">Np</forename><surname>Quinn</surname></persName></author><author><persName><forename type="first">L</forename><surname>Barbato</surname></persName></author><author><persName><forename type="first">Pn</forename><surname>Patsalos</surname></persName></author><author><persName><forename type="first">O</forename><surname>Connel</surname></persName></author><author><persName><forename type="first">S</forename><surname>Ruggieri</surname></persName></author><author><persName><forename type="first">Cd</forename><surname>Marsden</surname></persName></author></analytic><monogr><title level="j">Clin Neuropharmacol</title><imprint><biblScope unit="volume">17</biblScope><biblScope unit="page" from="38" to="44"></biblScope><date type="published" when="1994"></date></imprint></monogr></biblStruct><biblStruct xml:id="b47"><analytic><title level="a" type="main">Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease</title><author><persName><forename type="first">Rd</forename><surname>Sweet</surname></persName></author><author><persName><forename type="first">H</forename><surname>Fletcher</surname></persName></author><author><persName><forename type="first">Mc</forename><surname>Dowell</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">24</biblScope><biblScope unit="page" from="953" to="956"></biblScope><date type="published" when="1974"></date></imprint></monogr></biblStruct><biblStruct xml:id="b48"><analytic><title level="a" type="main">Patterns of clinical response and plasma dopa levels in Parkinson's disease</title><author><persName><forename type="first">Es</forename><surname>Tolosa</surname></persName></author><author><persName><forename type="first">We</forename><surname>Martin</surname></persName></author><author><persName><forename type="first">Hp</forename><surname>Cohen</surname></persName></author><author><persName><forename type="first">Rl</forename><surname>Jakobsen</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">25</biblScope><biblScope unit="page" from="177" to="183"></biblScope><date type="published" when="1975"></date></imprint></monogr></biblStruct><biblStruct xml:id="b49"><analytic><title level="a" type="main">Quantitative assessment of parkinsonian patients by continuous wrist activity monitoring</title><author><persName><forename type="first">Jj</forename><surname>Van Hilten</surname></persName></author><author><persName><forename type="first">G</forename><surname>Hoogland</surname></persName></author><author><persName><surname>Van Der</surname></persName></author><author><persName><forename type="first">Ea</forename><surname>Velde</surname></persName></author><author><persName><forename type="first">Jg</forename><surname>Van Dijk</surname></persName></author><author><persName><forename type="first">Ga</forename><surname>Kerkhof</surname></persName></author><author><persName><forename type="first">Ra</forename><surname>Roos</surname></persName></author></analytic><monogr><title level="j">Clin Neuropharmacol</title><imprint><biblScope unit="volume">16</biblScope><biblScope unit="page" from="36" to="45"></biblScope><date type="published" when="1993"></date></imprint></monogr></biblStruct><biblStruct xml:id="b50"><analytic><title level="a" type="main">Where to record motor activity: an evaluation of commonly used sites of placement for activity monitors</title><author><persName><forename type="first">Jj</forename><surname>Van Hilten</surname></persName></author><author><persName><forename type="first">Ha</forename><surname>Middelkoop</surname></persName></author><author><persName><forename type="first">Si</forename><surname>Kuiper</surname></persName></author><author><persName><forename type="first">Cg</forename><surname>Kramer</surname></persName></author><author><persName><forename type="first">Ra</forename><surname>Roos</surname></persName></author></analytic><monogr><title level="j">Electroencephalogr Clin Neurophysiol</title><imprint><biblScope unit="volume">89</biblScope><biblScope unit="page" from="359" to="362"></biblScope><date type="published" when="1993"></date></imprint></monogr></biblStruct><biblStruct xml:id="b51"><analytic><title level="a" type="main">Critical analysis of the disability in Parkinson's disease</title><author><persName><forename type="first">Dd</forename><surname>Webster</surname></persName></author></analytic><monogr><title level="j">Modern Treatment</title><imprint><biblScope unit="volume">5</biblScope><biblScope unit="page" from="257" to="282"></biblScope><date type="published" when="1968"></date></imprint></monogr></biblStruct></listBibl></back></text></istex:refBibTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000279 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000279 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:D8EA2B549FFC2A9C3FB429DACF1357BA7B14887F
|texte= Sustained-release of levodopa: single dose study of a new formulation
}}
| This area was generated with Dilib version V0.6.23. |  |